Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M. Bergaglio is active.

Publication


Featured researches published by M. Bergaglio.


Journal of Clinical Oncology | 1999

Comparative Effects of Paclitaxel and Docetaxel on the Metabolism and Pharmacokinetics of Epirubicin in Breast Cancer Patients

Mauro Esposito; M. Venturini; Maria O. Vannozzi; G. Tolino; Gianluigi Lunardi; Ornella Garrone; Catia Angiolini; Maurizio Viale; M. Bergaglio; L. Del Mastro; R. Rosso

PURPOSE To investigate whether paclitaxel and docetaxel influence the pharmacokinetics and metabolism of epirubicin. PATIENTS AND METHODS We studied the pharmacokinetics and biotransformation patterns of epirubicin in 27 cycles and 20 breast cancer patients. Four patients received epirubicin alone 90 mg/m(2) by intravenous (IV) bolus; eight patients received the same dose of epirubicin followed immediately by paclitaxel 175 mg/m(2) in a 3-hour infusion; the other eight patients received epirubicin 90 mg/m(2) followed immediately by docetaxel 70 mg/m(2) in a 1-hour infusion. Epirubicin and its metabolites, epirubicinol (EOL) and 7-deoxydoxorubicinone (7d-Aone), were identified by high-pressure liquid chromatography. RESULTS No pharmacokinetic interaction between the parent compound epirubicin and taxanes was detected. Conversely, a significant effect on epirubicin metabolism by both paclitaxel and docetaxel was found. Epirubicin given with paclitaxel or docetaxel yielded areas under the plasma concentration-time curves (AUC) for 7d-Aone 1. 7-fold and 1.9-fold higher (P <.05), respectively, than epirubicin alone. The appearance of two polar metabolites sensitive to glucuronidase was also significantly greater in both taxane groups. Quantitatively different metabolic rates and patterns for EOL were observed in the paclitaxel and docetaxel combinations. The EOL AUC after paclitaxel treatment (1,521 +/- 150 ng/mL*h) was significantly higher (P <.01) than the corresponding values after epirubicin administered either as a single agent (692 +/- 46 ng/mL*h) or in combination with docetaxel (848 +/- 237 ng/mL*h). CONCLUSION There is no apparent pharmacokinetic interaction between the parent compound epirubicin and paclitaxel or docetaxel. A different pattern of interaction between these taxanes and epirubicin metabolism is clearly evident.


European Journal of Cancer | 2002

Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients

L. Del Mastro; Massimo Costantini; Gabriella Morasso; Francesca Bonci; M. Bergaglio; S. Banducci; Paola Viterbori; Pierfranco Conte; R. Rosso; M. Venturini

In order to improve outcome, new, often more toxic chemotherapy regimens are continuously investigated in early breast cancer patients. Because the expected survival improvement is small, the possible increase in the negative effects of the new treatments should be carefully evaluated. Negative effects are represented not only by acute and chronic toxicity, but also by the adverse psychological impact of chemotherapy. The aim of this study was to evaluate the effect on patient-reported psychological distress of an increase in the dose-intensity of adjuvant chemotherapy compared with a standard regimen. Psychological distress was evaluated at baseline, during chemotherapy and after 6 and 12 months in breast cancer patients enrolled in a phase III multicentre study comparing the standard adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil every 21 days (CEF21) with the same chemotherapy given every 14 days (CEF14). 392 patients were randomised in participating centres, and 363 were evaluable for this study. Overall, 1095 out of 1446 expected questionnaires (75.7%) were collected and evaluable. At baseline, the mean scores of psychological distress were similar in the two arms. During chemotherapy, a significantly higher psychological distress was observed in the CEF14 compared with the CEF21 arm (32.3 +/- 1.3 versus 27.6 +/- 1.3; P=0.009), as well as a higher cumulative incidence of anaemia, mucositis, diarrhoea, alopecia, bone pain and fatigue was observed in the CEF14 arm. In multivariate analyses, mucositis (P=0.01), asthenia (P=0.059), and CEF14 treatment (P=0.054) were independently associated with a higher psychological distress. After 6 months, psychological distress was again similar in the two arms and significantly lower when compared with baseline within each arm. A dose-intensive adjuvant regimen induces a higher, although transient, psychological distress in early breast cancer patients. Final results of the randomised trial will indicate whether such higher adverse effects of the dose-intensive regimen are counterbalanced by a higher efficacy of the experimental treatment in terms of survival.


Annals of Oncology | 2001

Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients

M. Venturini; Andrea Michelotti; Paola Papaldo; L. Del Mastro; M. Bergaglio; Rita Lionetto; Gianluigi Lunardi; C. Sguotti; L. Frevola; S. Donati; R. Rosso; Francesco Cognetti

PURPOSE To determine the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of docetaxel in combination with fixed doses of epirubicin. PATIENTS AND METHODS Women with locally advanced or metastatic breast cancer were given docetaxel, 60 mg/m2 in escalated doses by steps of 10 mg/m2, in association with two fixed doses of epirubicin (90 mg/m2, and 75 mg/m2). Since neutropenia was foreseen to be the most likely DLT, a third group with prophylactic G-CSF support was planned to define the MTD of docetaxel with 90 mg/m2 of epirubicin. Selected patients underwent pharmacokinetic evaluation of docetaxel. RESULTS Fifty-eight patients entered the study. At the first step (90 mg/m2 of epirubicin) the MTD was obtained at 60 mg/m2 of docetaxel. At the second step (75 mg/m2 of epirubicin) the MTD of docetaxel was 80 mg/m2. At the third step (epirubicin 90 mg/m2) G-CSF allowed a safe escalation of docetaxel up to 90 mg/m2. Neutropenia was the most common hematological adverse event. Without G-CSF, grade 4 neutropenia occurred in 69% of cycles, of which 11% was complicated by fever. In G-CSF group, grade 4 neutropenia and neutropenic fever occurred in 31% and 3%, respectively. Most frequent non-hematological adverse effects were asthenia (45%), nausea (39%) and mucositis (36%). No patient developed congestive heart failure. Two toxic deaths occurred. Overall response rate was 73% in 42 out of 58 patients, with no apparent epirubicin dose-related effect. No statistically significant effect of the two doses of epirubicin was observed in docetaxel pharmacokinetics. CONCLUSIONS On the basis of the toxicity profile, the docetaxel pharmacokinetics and the response rate observed, epirubicin 75 mg/m2 combined with docetaxel 80 mg/m2 can be recommended for further studies.


Annals of Oncology | 2001

Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients

L. Del Mastro; M. Venturini; C. Viscoli; M. Bergaglio; A. Signorini; Claudia Bighin; Gianfilippo Bertelli; C. Semino; G. Pietra; S. Bertoglio; Mario Roberto Sertoli; A. Lambiase; R. Rosso; G. Melioli

BACKGROUND The majority of high-dose chemotherapy (HDC)-related complications results from bone marrow aplasia, but the graft infusion per se may cause adverse reactions due to the injection of both dimethyl sulfoxide (DMSO) and cell lysis products. We evaluated the feasibility of a two-step chemotherapy regimen with peripheral blood progenitor cell (PBPC) support in association with a novel procedure to remove DMSO and products of cell lysis from the cryopreserved cells. PATIENTS AND METHODS Stage III and IV breast cancer patients received induction chemotherapy with three cycles of CEF (cyclophosphamide 600 mg/m2, epirubicin 100 mg/m2, 5-fluorouracil 600 mg/m2) followed by three cycles of HDC consisting of escalating doses of cyclophosphamide (dose range 1200 3000 mg/m2) and carboplatin (dose range 600-1000 mg/m2), supported by DMSO-free PBPC reinfusion. DMSO was removed by a washing/enzymatic digestion procedure. RESULTS Twenty patients received induction chemotherapy and eighteen completed the entire chemotherapy program; a total of fifty-four cycles of HDC were administered. Dose limiting toxicity of HDC was long-lasting grade 4 neutropenia associated with documented infection. The maximum tolerated dose (MTD) was cyclophosphamide 3000 mg/m2 and carboplatin 600 mg/m2. No side effects related to PBPC reinfusion were observed. CONCLUSIONS The proposed two-step chemotherapy regimen, associated with a novel washing/enzymatic digestion procedure, is feasible in advanced breast cancer patients in the absence of complications related to the specific toxicity of PBPC reinfusion.


European Journal of Cancer | 1996

89 O - Effecf of previous adjuvant chemotherapy on the activity and efficacy of cef regimen in metastatic breast cancer patients

L. Del Mastro; M. Venturini; Ornella Garrone; Paolo Bruzzi; Gianfilippo Bertelli; M. Bergaglio; Mario Roberto Sertoli; R. Rosso

The effect of previous adjuvant chemotherapy (ACT) with or without anthracyclines on response rate (RR), progression free survival (PFS) and overali survival (OS) was evaluated in 326 metastatic breast cancer patients treated with CEF (Cyclophosphamide, Epidoxorubicin, FIuorouracil)-based regimens, as first line chemotherapy. One hundred forty-four patients (44%) did not receive ACT, 143 (44%) received CMF-based ACT and 39 (12%) anthracycline-based ACT. Univariate analysis showed a lower probability of response in patients previously treated with ACT (RR=43%) than in patients who did not (RR=58%; p=.02). No difference between CMF-based and anthracycline-based ACT was observed. A longer OS was observed in patients who did not receive ACT (21.1 months) compared to patients previously treated with CMF-based (15.3 months) or anthracycline-based (15.8 months) ACT. Multivariate analysis confirmed ACT as an indipendent prognostic factor associated with a poor RR, PFS and OS. Previous ACT adversely affects the activity and efficacy of CEF, when used as first line regimen in metastatic breast cancer patients. No difference between CMF·hased and anthracycline-based ACT was observed. Because of the poorer activity and efficacy observed, patients who relapse after ACT should be considered for treatment With new drugs or new strategies.


Annals of Oncology | 2002

Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study

Gianfilippo Bertelli; M. Venturini; L. Del Mastro; M. Bergaglio; Piero Sismondi; Nicoletta Biglia; S. Venturini; G. Porcile; Paolo Pronzato; Massimo Costantini; R. Rosso


Annals of Oncology | 2002

Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer

M. Venturini; L. Del Mastro; Ornella Garrone; Catia Angiolini; Marco Merlano; M. Bergaglio; G. Tolino; Antonio Lambiase; A. Baldini; G. Canavese; R. Rosso


Breast Cancer Research and Treatment | 2000

Capecitabine in association with epirubicin and docetaxel as first line chemotherapy in advanced breast cancer A dose-finding study

Catia Angiolini; M. Venturini; L. Del Mastro; G. Tolino; Ornella Garrone; Marco Merlano; M. Bergaglio; Gianfilippo Bertelli; Antonio Lambiase; I. Stevani; Claudia Bighin; T. Catzeddu; R. Rosso


Tumori | 1997

USO DELL'ERITROPOIETINA IN ONCOLOGIA

R. Rosso; L. Del Mastro; M. Venturini; M. Bergaglio; W. Pasquetti; Ornella Garrone


Annals of Oncology | 2001

Erratum: Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients (Annals of Oncology (2001) vol. 12 (8) (1097-1106))

M. Venturini; Andrea Michelotti; Paola Papaldo; L. Del Mastro; M. Bergaglio; Rita Lionetto; Gianluigi Lunardi; C. Sguotti; L. Frevola; S. Donati; R. Rosso; Francesco Cognetti

Collaboration


Dive into the M. Bergaglio's collaboration.

Top Co-Authors

Avatar

M. Venturini

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar

R. Rosso

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar

L. Del Mastro

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Massimo Costantini

National Cancer Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge